• LAST PRICE
    0.3399
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.3400/ 3
  • Ask / Lots
    0.4222/ 38
  • Open / Previous Close
    0.0000 / 0.3399
  • Day Range
    ---
  • 52 Week Range
    Low 0.2402
    High 1.1774
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.338
TimeVolumeVRPX
09:32 ET9700.34
09:33 ET448310.34
09:39 ET2000.34
09:50 ET1500.336667
10:02 ET50000.3367
10:09 ET2680.3399
10:22 ET77170.34
10:36 ET25720.34
10:38 ET11000.3399
10:49 ET5000.3374
11:20 ET2050.336
11:34 ET3000.339899
12:10 ET21000.335
12:14 ET150410.335
12:28 ET10000.338
01:00 ET5990.335
01:26 ET1680.3415
03:03 ET2000.3415
03:57 ET10880.3399
04:00 ET1170.3399
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVRPX
Virpax Pharmaceuticals Inc
4.0M
-0.3x
---
United StatesKTRA
Kintara Therapeutics Inc
4.0M
0.0x
---
United StatesBZYR
Burzynski Research Institute Inc
3.9M
-3.3x
---
United StatesPTIX
Protagenic Therapeutics Inc
3.9M
-1.0x
---
United StatesIPIX
Innovation Pharmaceuticals Inc
4.1M
-1.6x
---
United StatesKRBP
Kiromic Biopharma Inc
3.9M
-0.1x
---
As of 2024-02-27

Company Information

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.

Contact Information

Headquarters
1055 Westlakes Drive, Suite 300BERWYN, PA, United States 19312
Phone
610-727-4597
Fax
302-636-5454

Executives

Chairman of the Board
Eric Floyd
Chief Executive Officer, Executive Vice President, Commercial Operations Officer, Director
Gerald Bruce
Chief Financial Officer
Vinay Shah
Executive Vice President, Director, Chief Medical Officer
Jeffrey Gudin
Independent Director
Michael Dubin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.0M
Revenue (TTM)
$0.00
Shares Outstanding
11.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.16
Book Value
$1.42
P/E Ratio
-0.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.